pamidronate has been researched along with Osteoporosis, Postmenopausal in 43 studies
Osteoporosis, Postmenopausal: Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study was a 1-yr randomized, double-blind, placebo-controlled trial comparing pamidronate 60 mg iv every 3 months with placebo in 40 premenopausal women with newly diagnosed breast cancer." | 9.11 | Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. ( Chehal, A; Fuleihan, Gel-H; Mahfoud, Z; Mourad, YA; Salamoun, M; Salem, Z; Shamseddine, A, 2005) |
| "The effect of oral pamidronate on bone mineral density and its adverse effect profile was investigated by a double-masked placebo-controlled study of 122 patients aged 55-75 years with established vertebral osteoporosis." | 9.09 | Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety. ( Blake, GM; Davie, M; Fogelman, I; Gibson, T; Haddaway, M; Ryan, PJ, 2000) |
| " administration of disodium pamidronate can effectively achieve primary prevention of glucocorticoid-induced osteoporosis (GIOP)." | 9.08 | Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. ( Boutsen, Y; Devogelaer, JP; Esselinckx, W; Jamart, J; Stoffel, M, 1997) |
| "The purpose of this study is to evaluate the acute effect of pamidronate on plasma ionized calcium (iCa) level reduction and dynamic parathyroid hormone (PTH) secretion in postmenopausal hemodialysis-dependent women with secondary hyperparathyroidism." | 7.72 | Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. ( Chu, P; Lin, SH; Lin, YF; Lu, KC; Yeung, LK, 2003) |
| "We describe the case of a patient who developed reversible retrobulbar optic neuritis after intravenous pamidronate therapy for established osteoporosis." | 7.69 | Retrobulbar optic neuritis after pamidronate administration in a patient with a history of cutaneous porphyria. ( Body, JJ; des Grottes, JM; Dumon, JC; Schrooyen, M, 1997) |
| "The study was a 1-yr randomized, double-blind, placebo-controlled trial comparing pamidronate 60 mg iv every 3 months with placebo in 40 premenopausal women with newly diagnosed breast cancer." | 5.11 | Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. ( Chehal, A; Fuleihan, Gel-H; Mahfoud, Z; Mourad, YA; Salamoun, M; Salem, Z; Shamseddine, A, 2005) |
| "The effect of oral pamidronate on bone mineral density and its adverse effect profile was investigated by a double-masked placebo-controlled study of 122 patients aged 55-75 years with established vertebral osteoporosis." | 5.09 | Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety. ( Blake, GM; Davie, M; Fogelman, I; Gibson, T; Haddaway, M; Ryan, PJ, 2000) |
| " administration of disodium pamidronate can effectively achieve primary prevention of glucocorticoid-induced osteoporosis (GIOP)." | 5.08 | Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. ( Boutsen, Y; Devogelaer, JP; Esselinckx, W; Jamart, J; Stoffel, M, 1997) |
| " The parent compound, etidronate, was first used in multicentered trials for the treatment of primary osteoporosis and showed some success in increasing bone density and perhaps controlling fracture rates." | 4.79 | Bisphosphonate therapy. ( Licata, AA, 1997) |
| " Bisphosphonate-treated women with postmenopausal or glucocorticoid-induced osteoporosis showed adequate and consistent changes of bone markers to subsequently administered intravenous pamidronate." | 3.79 | Long-term treatment of osteoporotic women with bisphosphonates does not impair the response to subsequently administered intravenous pamidronate. ( Hamdy, NA; Papapoulos, SE; Yavropoulou, MP, 2013) |
| "The purpose of this study is to evaluate the acute effect of pamidronate on plasma ionized calcium (iCa) level reduction and dynamic parathyroid hormone (PTH) secretion in postmenopausal hemodialysis-dependent women with secondary hyperparathyroidism." | 3.72 | Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. ( Chu, P; Lin, SH; Lin, YF; Lu, KC; Yeung, LK, 2003) |
| "We describe the case of a patient who developed reversible retrobulbar optic neuritis after intravenous pamidronate therapy for established osteoporosis." | 3.69 | Retrobulbar optic neuritis after pamidronate administration in a patient with a history of cutaneous porphyria. ( Body, JJ; des Grottes, JM; Dumon, JC; Schrooyen, M, 1997) |
| "Pamidronate is an effective inhibitor of bone resorption; for this reason it is used in the treatment of high bone turnover diseases and osteoporosis." | 2.69 | [Treatment of post menopausal osteoporosis with intravenous pamidronate in patients with esophagogastric pathology]. ( Fradinger, E; Morillo, S; Rey, P; Sarli, M; Zanchetta, J, 1998) |
| "Free deoxypyridinoline (f-DPD) was measured in fasting urine specimens." | 2.69 | Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. ( Adami, S; Braga, V; Fracassi, E; Gatti, D; Gerardi, D; Guidi, G, 2000) |
| "We have performed a 2-year prospective double-masked study to determine whether the bisphosphonate pamidronate can prevent bone loss in postmenopausal women and its optimal dosage regimen." | 2.68 | Role of oral pamidronate in preventing bone loss in postmenopausal women. ( Garland, SW; Lees, B; Ross, D; Stevenson, JC; Walton, C; Whitehead, MI, 1996) |
| " The effect of intravenous infusions of bisphosphonates are, to a large extent, similar to equivalent intramuscular administrations, but doses and dosing intervals represent the critical issues." | 2.42 | Injectable bisphosphonates in the treatment of postmenopausal osteoporosis. ( Adami, S; Crepaldi, G; Filipponi, P; Sartori, L, 2003) |
| " In this work, disodium pamidronate was complexed with phospholipon 90G for the enhancement of permeability and to investigate the phospholipon 90G-tagged pamidronate complex-loaded SNEDDS for oral delivery with promises of enhanced bioavailability and anti-osteoporotic activity." | 1.91 | Precision engineering designed phospholipid-tagged pamidronate complex functionalized SNEDDS for the treatment of postmenopausal osteoporosis. ( Ahmad, FJ; Alam, MI; Ansari, MD; Aqil, M; Solanki, P; Sultana, Y, 2023) |
| " Antifracture efficacy has been demonstrated for at least three nitrogen-containing bisphosphonates in oral formulations that are designed to be administered in weekly or monthly dosing regimens." | 1.34 | Use of intravenous bisphosphonates in osteoporosis. ( Armamento-Villareal, R; Civitelli, R; Napoli, N, 2007) |
| "Mild anterior uveitis is an unfamiliar adverse effect of pamidronate therapy." | 1.34 | Bilateral severe fibrinous anterior uveitis--an unusual complication of pamidronate therapy exacerbated by topical latanoprost. ( Palimar, P; Quah, S; Ramasamy, B; Sahni, JN, 2007) |
| " Current reports have focused on therapy-resistant osteonecrosis of the jaws as a possible side effect of bisphosphonates." | 1.33 | [Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates]. ( Eufinger, H; Hoefert, S, 2005) |
| "The total number of new bone fractures and total number of patients with new fractures were less frequent during the pamidronate treatment period than before (p < 0." | 1.30 | [Extended use, up to 6 years, of an oral amino-bisphosphonate in patients with established osteoporosis]. ( Bogado, C; Plotkin, H; Roldán, EJ; Sarli, M; Spivacow, RF; Zanchetta, JR, 1997) |
| " In osteoporotic syndromes, APD is prescribed at a lower dosage (200 mg/day) and currently calcium or vitamin D are also systematically added." | 1.29 | [Effect of low doses of oral pamidronate (APD) on the calcemia of osteopenic or osteoporotic patients]. ( Castelli, G; Kerzberg, EM; Lloret, AP; Roldan, EJ, 1996) |
| "Pamidronate was given continuously during 18 months in a daily oral dose of 4." | 1.28 | Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis. ( Fromm, GA; Galich, AM; Mautalen, CA; Plantalech, L; Vega, E, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 21 (48.84) | 18.2507 |
| 2000's | 18 (41.86) | 29.6817 |
| 2010's | 3 (6.98) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Solanki, P | 3 |
| Ansari, MD | 3 |
| Alam, MI | 3 |
| Aqil, M | 3 |
| Ahmad, FJ | 3 |
| Sultana, Y | 3 |
| Yavropoulou, MP | 1 |
| Hamdy, NA | 1 |
| Papapoulos, SE | 3 |
| Geusens, P | 1 |
| Jenkinson, E | 1 |
| Cella, L | 1 |
| Oppici, A | 1 |
| Arbasi, M | 1 |
| Moretto, M | 1 |
| Piepoli, M | 1 |
| Vallisa, D | 1 |
| Zangrandi, A | 1 |
| Di Nunzio, C | 1 |
| Cavanna, L | 1 |
| Younes, H | 1 |
| Farhat, G | 1 |
| el-Hajj Fuleihan, G | 1 |
| Heijckmann, AC | 1 |
| Juttmann, JR | 1 |
| Wolffenbuttel, BH | 1 |
| Peretz, A | 2 |
| Siderova, V | 1 |
| Body, JJ | 3 |
| Dumon, JC | 3 |
| Rozenberg, S | 2 |
| Fellemans, C | 1 |
| Fuss, M | 1 |
| Bergmann, P | 2 |
| Morabito, N | 1 |
| Gaudio, A | 1 |
| Lasco, A | 1 |
| Vergara, C | 1 |
| Tallarida, F | 1 |
| Crisafulli, G | 1 |
| Trifiletti, A | 1 |
| Cincotta, M | 1 |
| Pizzoleo, MA | 1 |
| Frisina, N | 1 |
| Lu, KC | 1 |
| Yeung, LK | 1 |
| Lin, SH | 1 |
| Lin, YF | 1 |
| Chu, P | 1 |
| Sartori, L | 1 |
| Adami, S | 2 |
| Filipponi, P | 1 |
| Crepaldi, G | 1 |
| Fuleihan, Gel-H | 1 |
| Salamoun, M | 1 |
| Mourad, YA | 1 |
| Chehal, A | 1 |
| Salem, Z | 1 |
| Mahfoud, Z | 1 |
| Shamseddine, A | 1 |
| Hoefert, S | 1 |
| Eufinger, H | 1 |
| Laroche, M | 1 |
| Bret, J | 1 |
| Brouchet, A | 1 |
| Mazières, B | 1 |
| Mosekilde, L | 1 |
| Vestergaard, P | 1 |
| Langdahl, B | 1 |
| Civitelli, R | 1 |
| Napoli, N | 1 |
| Armamento-Villareal, R | 1 |
| Ramasamy, B | 1 |
| Quah, S | 1 |
| Sahni, JN | 1 |
| Palimar, P | 1 |
| Sari, E | 1 |
| Bulut, N | 1 |
| Altundag, K | 1 |
| Garnero, P | 1 |
| Gineyts, E | 1 |
| Arbault, P | 1 |
| Christiansen, C | 1 |
| Delmas, PD | 1 |
| Reid, IR | 2 |
| Wattie, DJ | 2 |
| Evans, MC | 2 |
| Gamble, GD | 1 |
| Stapleton, JP | 1 |
| Cornish, J | 1 |
| Thiébaud, D | 1 |
| Burckhardt, P | 1 |
| Melchior, J | 1 |
| Eckert, P | 1 |
| Jacquet, AF | 1 |
| Schnyder, P | 1 |
| Gobelet, C | 1 |
| Calligeros, D | 1 |
| Douglas, P | 1 |
| Abeygunasekera, S | 1 |
| Smith, G | 1 |
| Erdtsieck, RJ | 1 |
| Pols, HA | 1 |
| Valk, NK | 1 |
| van Ouwerkerk, BM | 1 |
| Lamberts, SW | 1 |
| Mulder, P | 1 |
| Birkenhäger, JC | 1 |
| Zanchetta, JR | 2 |
| Plotkin, H | 2 |
| Roldán, EJ | 4 |
| Hotimski, A | 1 |
| Praet, JP | 1 |
| Moris, M | 1 |
| Ham, H | 1 |
| Kerzberg, EM | 1 |
| Castelli, G | 1 |
| Lloret, AP | 1 |
| Licata, AA | 1 |
| Orr-Walker, B | 1 |
| Lees, B | 1 |
| Garland, SW | 1 |
| Walton, C | 1 |
| Ross, D | 1 |
| Whitehead, MI | 1 |
| Stevenson, JC | 1 |
| des Grottes, JM | 1 |
| Schrooyen, M | 1 |
| Barreira, JC | 1 |
| Messina, OD | 1 |
| Maldonado-Cocco, JA | 1 |
| Boutsen, Y | 1 |
| Jamart, J | 1 |
| Esselinckx, W | 1 |
| Stoffel, M | 1 |
| Devogelaer, JP | 1 |
| Kollerup, G | 1 |
| Sørensen, HA | 1 |
| Hyldstrup, L | 1 |
| Storm, T | 1 |
| Man, Z | 1 |
| Otero, AB | 1 |
| Spivacow, RF | 1 |
| Bogado, C | 1 |
| Sarli, M | 2 |
| Fradinger, E | 1 |
| Morillo, S | 1 |
| Rey, P | 1 |
| Zanchetta, J | 1 |
| Braga, V | 1 |
| Guidi, G | 1 |
| Gatti, D | 1 |
| Gerardi, D | 1 |
| Fracassi, E | 1 |
| Ryan, PJ | 1 |
| Blake, GM | 1 |
| Davie, M | 1 |
| Haddaway, M | 1 |
| Gibson, T | 1 |
| Fogelman, I | 1 |
| Watts, NB | 1 |
| Fromm, GA | 1 |
| Vega, E | 1 |
| Plantalech, L | 1 |
| Galich, AM | 1 |
| Mautalen, CA | 1 |
| Lockefeer, JH | 1 |
| Papapoulos, S | 1 |
8 reviews available for pamidronate and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Frac | 2009 |
Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: do bisphosphonates relieve pain caused by acute osteoporotic vertebral compression fractures?
Topics: Administration, Oral; Aged; Back Pain; Bone Density Conservation Agents; Diphosphonates; Female; Fra | 2011 |
Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.
Topics: Anti-Inflammatory Agents; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazole | 2003 |
Fracture prevention in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphon | 2006 |
Bisphosphonate therapy.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; | 1997 |
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; | 2000 |
Treatment of osteoporosis with bisphosphonates.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Fem | 2001 |
[Diphosphonates in the treatment of osteoporosis].
Topics: Aged; Diphosphonates; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postm | 1991 |
13 trials available for pamidronate and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Response to alendronate in osteoporotic women previously treated with pamidronate.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Bone Density; Calcium; Collagen; Diet | 2003 |
Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis.
Topics: Alkaline Phosphatase; Bone Density; Bone Resorption; Calcium; Diphosphonates; Drug Therapy, Combinat | 2003 |
Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calc | 2005 |
Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis.
Topics: Aged; Alkaline Phosphatase; Bone Density; Calcium; Diphosphonates; Double-Blind Method; Female; Huma | 1994 |
Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density; Diphosphonates; Female; Femur Ne | 1994 |
Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial.
Topics: Aged; Body Composition; Bone Density; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Fe | 1995 |
Role of oral pamidronate in preventing bone loss in postmenopausal women.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Bone Density; Diphosphonates; Double-Blind Metho | 1996 |
Site-dependent bone mineral density response to oral pamidronate and calcium in postmenopausal osteoporosis: a preliminary report.
Topics: Adult; Aged; Bone Density; Calcium; Diphosphonates; Drug Therapy, Combination; Female; Femur; Femur | 1997 |
Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial.
Topics: Absorptiometry, Photon; Adult; Aged; Anti-Inflammatory Agents; Biomarkers; Bone Density; Calcium; Di | 1997 |
Assessment of different markers of bone resorption in postmenopausal osteoporotic women treated with pamidronate.
Topics: Aged; Amino Acids; Biomarkers; Bone Resorption; Chromatography, High Pressure Liquid; Diphosphonates | 1997 |
[Treatment of post menopausal osteoporosis with intravenous pamidronate in patients with esophagogastric pathology].
Topics: Aged; Diphosphonates; Esophageal Diseases; Female; Humans; Infusions, Intravenous; Middle Aged; Oste | 1998 |
Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; | 2000 |
Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety.
Topics: Administration, Oral; Aged; Analysis of Variance; Anti-Inflammatory Agents; Bone Density; Diphosphon | 2000 |
22 other studies available for pamidronate and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Precision engineering designed phospholipid-tagged pamidronate complex functionalized SNEDDS for the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Biological Availability; Drug Delivery Systems; Emulsions; Female; Humans; Nan | 2023 |
Precision engineering designed phospholipid-tagged pamidronate complex functionalized SNEDDS for the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Biological Availability; Drug Delivery Systems; Emulsions; Female; Humans; Nan | 2023 |
Precision engineering designed phospholipid-tagged pamidronate complex functionalized SNEDDS for the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Biological Availability; Drug Delivery Systems; Emulsions; Female; Humans; Nan | 2023 |
Precision engineering designed phospholipid-tagged pamidronate complex functionalized SNEDDS for the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Biological Availability; Drug Delivery Systems; Emulsions; Female; Humans; Nan | 2023 |
Precision engineering designed phospholipid-tagged pamidronate complex functionalized SNEDDS for the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Biological Availability; Drug Delivery Systems; Emulsions; Female; Humans; Nan | 2023 |
Precision engineering designed phospholipid-tagged pamidronate complex functionalized SNEDDS for the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Biological Availability; Drug Delivery Systems; Emulsions; Female; Humans; Nan | 2023 |
Precision engineering designed phospholipid-tagged pamidronate complex functionalized SNEDDS for the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Biological Availability; Drug Delivery Systems; Emulsions; Female; Humans; Nan | 2023 |
Precision engineering designed phospholipid-tagged pamidronate complex functionalized SNEDDS for the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Biological Availability; Drug Delivery Systems; Emulsions; Female; Humans; Nan | 2023 |
Precision engineering designed phospholipid-tagged pamidronate complex functionalized SNEDDS for the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Biological Availability; Drug Delivery Systems; Emulsions; Female; Humans; Nan | 2023 |
Long-term treatment of osteoporotic women with bisphosphonates does not impair the response to subsequently administered intravenous pamidronate.
Topics: Administration, Oral; Adult; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Colla | 2013 |
Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw.
Topics: Aged; Diphosphonates; Female; Humans; Injections, Intralesional; Jaw Diseases; Osteonecrosis; Osteop | 2011 |
Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass.
Topics: Adult; Aged; Bone Density; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Injections, Int | 2002 |
Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Diphosphonates; Female; Fractures, Spontaneou | 2002 |
Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
Topics: Aged; Chronic Kidney Disease-Mineral and Bone Disorder; Diphosphonates; Female; Humans; Hypercalcemi | 2003 |
[Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates].
Topics: Aged; Alendronate; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular D | 2005 |
Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Bone Density; Bone Marrow Cells; Bone Remodeling; Diphosphona | 2007 |
Use of intravenous bisphosphonates in osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandroni | 2007 |
Bilateral severe fibrinous anterior uveitis--an unusual complication of pamidronate therapy exacerbated by topical latanoprost.
Topics: Acute Disease; Administration, Topical; Aged, 80 and over; Anti-Inflammatory Agents; Bone Density Co | 2007 |
Osteonecrosis of the jaw.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Jaw Dis | 2008 |
Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion.
Topics: Adult; Aged; Aged, 80 and over; Amino Acids; Bone Development; Chemical Fractionation; Chromatograph | 1995 |
Aseptic peritonitis in association with the use of pamidronate.
Topics: Diphosphonates; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Peritonitis | 1993 |
Mineral density gain in vertebrae of osteoporotic women on oral pamidronate reverts a year after treatment discontinuance.
Topics: Administration, Oral; Bone Density; Diphosphonates; Female; Femur Neck; Humans; Lumbar Vertebrae; Os | 1996 |
Cyclical pamidronate infusions in postmenopausal osteoporosis.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Density; Bone Remodeling; Calcium; Diphosphonates; Drug Admi | 1996 |
[Effect of low doses of oral pamidronate (APD) on the calcemia of osteopenic or osteoporotic patients].
Topics: Administration, Oral; Analysis of Variance; Bone Diseases, Metabolic; Bone Resorption; Calcium, Diet | 1996 |
Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis.
Topics: Aged; Bone Density; Diphosphonates; Female; Femur; Follow-Up Studies; Humans; Lumbar Vertebrae; Oste | 1997 |
Retrobulbar optic neuritis after pamidronate administration in a patient with a history of cutaneous porphyria.
Topics: Anti-Inflammatory Agents; Diphosphonates; Evoked Potentials, Visual; Female; Humans; Infusions, Intr | 1997 |
[New spine and non-spine fractures in 871 women/year treated with oral pamidronate plus calcium and vitamin D supplements].
Topics: Accidental Falls; Bone Density; Calcium, Dietary; Diphosphonates; Female; Follow-Up Studies; Fractur | 1997 |
[Extended use, up to 6 years, of an oral amino-bisphosphonate in patients with established osteoporosis].
Topics: Administration, Oral; Bone Density; Bone Resorption; Diphosphonates; Drug Tolerance; Female; Follow- | 1997 |
Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis.
Topics: Aged; Bone Density; Cohort Studies; Diphosphonates; Female; Femur; Humans; Lumbar Vertebrae; Middle | 1991 |
[Diphosphonates in the treatment of osteoporosis].
Topics: Bone Density; Diphosphonates; Etidronic Acid; Female; Humans; Osteoporosis; Osteoporosis, Postmenopa | 1991 |